2-氯甲基-5-甲氧基吡嗪 | 1196156-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯甲基-5-甲氧基吡嗪
• 中文别名: 2-(氯甲基)-5-甲氧基吡嗪
• 英文名称: 2-(chloromethyl)-5-methoxypyrazine
• 英文别名: 2-(Chloromethyl)-5-methoxypyrazine
• CAS: 1196156-90-7
• 化学式: C₆H₇ClN₂O
• 分子量: 158.587
• InChiKey: RDZSXLXGRSWNAQ-UHFFFAOYSA-N

物化性质

• 沸点：
  229.1±35.0℃ (760 Torr)
• 密度：
  1.243±0.06 g/cm3 (20 ºC 760 Torr)
• 闪点：
  92.4±25.9℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氯甲基-5-甲氧基吡嗪 、 4-[(4-{[1-methyl-5-(piperidin-4-yl)-1H-indol-2-yl]carbonyl}piperazin-1-yl)methyl]benzonitrile 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 120.0h， 生成 4-({4-[(5-{1-[(5-methoxypyrazin-2-yl)methyl]piperidin-4-yl}-1-methyl-1H-indol-2-yl)carbonyl]piperazin-1-yl}methyl)benzonitrile
  参考文献：
  名称：

  PHARMACEUTICAL COMPOSITION HAVING BICYCLIC NITROGEN-CONTAINING AROMATIC HETROCYCLIC AMIDE COMPOUNDS AS ACTIVE INGREDIENT

  摘要：

  【问题】提供一种用于治疗涉及线粒体复合物I的各种癌症，特别是结肠癌、白血病和/或恶性淋巴瘤的药物组合物。【解决方案】通过创造用于治疗各种癌症的药物组合物的发明，发明人根据深入调查的结果确认，包含具有AMPK激活作用和涉及线粒体复合物I的特定双环氮杂芳香杂环酰胺化合物的药物组合物，特别是用于治疗结肠癌、白血病和/或恶性淋巴瘤；从而完成了本发明。

  公开号：

  EP3231426A1
• 作为产物：
  描述：

  5-氯吡嗪-2-羧酸甲酯 在 sodium tetrahydroborate 、 氯化亚砜 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.75h， 生成 2-氯甲基-5-甲氧基吡嗪
  参考文献：
  名称：

  Novel Indirect AMP-Activated Protein Kinase Activators: Identification of a Second-Generation Clinical Candidate with Improved Physicochemical Properties and Reduced hERG Inhibitory Activity

  摘要：

  This study reports the synthesis and evaluation of novel indirect AMP-activated protein kinase (AMPK) activators. The series of compounds selectively inhibited cell growth in several human breast cancer cell lines by activating AMPK. We performed back-up medicinal chemistry synthetic research on ASP4132, a previously reported as a compound for clinical development that acts as an indirect AMPK activator. This led to the successful identification of 4-({4-[5-({1-[(5-ethoxypyrazin-2-yl)methyl]-4-fluoropiperidin-4-yl}methoxy)-3-methylpyridine-2-carbonyl]piperazin-1-yl}methyl)benzonitrile succinate (27b), a potent, highly aqueous soluble and metabolically stable compound in human hepatocytes. Compound 27b also showed weaker human Ether-a-go-go Related Gene (hERG) inhibitory activity than that of compound 13 and ASP4132. Therefore, 27b was a promising AMPK activator and a second-generation clinical candidate for treatment for human cancer.

  DOI：

  10.1248/cpb.c20-00015

文献信息

• [EN] NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS<br/>[FR] NOUVEAUX COMPOSÉS DE TÉTRAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DE LA TUBERCULOSE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019034729A1

  公开（公告）日：2019-02-21

  The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

  这项发明涉及到式（I）的化合物或其药用盐以及它们在治疗中的应用，例如在治疗分枝杆菌感染或治疗由分枝杆菌引起的疾病，如结核病。
• BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND
  申请人：ASTELLAS PHARMA INC.

  公开号：US20150266869A1

  公开（公告）日：2015-09-24

  [Problem] A compound which is useful as an agent for treating breast cancer is provided. [Means for Solution] As a result of intensive studies on a compound having a Complex I inhibitory effect and an AMPK activation effect, the present inventors found that a bicyclic nitrogen-containing aromatic heterocyclic amide compounds of the present invention has an excellent Complex I inhibitory effect and the AMPK activation effect, furthermore, has a cell proliferation inhibitory effect with respect to not only human PIK3CA mutation-positive breast cancer cell lines in which MCT4 is not expressed but also human breast cancer cell lines which do not have mutation of PIK3CA in which MCT4 is not expressed, and exhibits an anti-tumor effect in a human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cell in a cancer-bearing mouse in which the MCT4 is not expressed, thereby completing the present invention. A bicyclic nitrogen-containing aromatic heterocyclic amide compound of the present invention can be used as an agent for treating breast cancer, in particular, breast cancer in which the MCT4 is not expressed, and among others, PIK3CA mutation-positive breast cancer in which the MCT4 is not expressed.

  提供一种作为治疗乳腺癌药物的化合物。通过对具有复合I抑制作用和AMPK激活作用的化合物进行深入研究，本发明人发现，本发明的含有双环氮杂芳香族酰胺化合物具有优异的复合I抑制作用和AMPK激活作用，此外，对于不仅在其中MCT4不表达的人类PIK3CA突变阳性乳腺癌细胞系，还对于其中MCT4不表达的不具有PIK3CA突变的人类乳腺癌细胞系，具有细胞增殖抑制作用，并在MCT4不表达的癌症携带小鼠的人类PIK3CA突变阳性乳腺癌细胞系MDA-MB-453细胞中表现出抗肿瘤作用，从而完成了本发明。本发明的含有双环氮杂芳香族酰胺化合物可用作治疗乳腺癌的药物，尤其是MCT4不表达的乳腺癌，以及其他MCT4不表达的PIK3CA突变阳性乳腺癌。
• PHARMACEUTICAL COMPOSITION HAVING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE COMPONENT
  申请人：Astellas Pharma Inc.

  公开号：EP3231425A1

  公开（公告）日：2017-10-18

  To provide a pharmaceutical composition for treating multiple myeloma. [Solution] After investigating compounds having a mitochondrial Complex I inhibitory effect, the present inventor completed the present invention by confirming that the bicyclic nitrogen-containing aromatic heterocyclic amide compounds of the present invention have a mitochondrial Complex I inhibitory effect, and that these compounds have a growth inhibition effect on multiple myeloma.

  提供一种用于治疗多发性骨髓瘤的药物组合物。【解决方案】在调查具有线粒体复合物I抑制作用的化合物后，本发明人通过确认本发明的双环氮杂芳香杂环酰胺化合物具有线粒体复合物I抑制作用，并且这些化合物对多发性骨髓瘤具有生长抑制作用，完成了本发明。
• [EN] INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF<br/>[FR] INHIBITEURS DE FGFR2 ET DE FGFR3 ET LEURS UTILISATIONS
  申请人：INSILICO MEDICINE IP LTD

  公开号：WO2024002157A1

  公开（公告）日：2024-01-04

  Provided are FGFR2 and FGFR3 inhibitors of Formula (I) and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with FGFR2 and/or FGFR3.

  本文提供了式 (I) 的 FGFR2 和 FGFR3 抑制剂以及包含上述抑制剂的药物组合物。这些化合物和组合物可用于治疗与 FGFR2 和/或 FGFR3 相关的疾病或紊乱。
• Tetrazole compounds and their use in the treatment of tuberculosis
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US11072591B2

  公开（公告）日：2021-07-27

  The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by Mycobacterium, such as tuberculosis.

  本发明涉及式（I）化合物或其药学上可接受的盐及其在治疗中的应用，例如在治疗分枝杆菌感染或治疗由分枝杆菌引起的疾病（如结核病）中的应用。